Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001767215Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE TESTSubmission Contact InformationIs this a Live of the second secon

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer	Charles River Laboratories
SEC File Number	001-15943
Address of Issuer	251 Ballardvale Street Wilmington MASSACHUSETTS 01887
Phone	781-222-6000
Name of Person for Whose Account the Securities are To Be Sold	Joseph LaPlume

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Officer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Charles River Laboratories	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	700	150500	51180000	08/10/2023	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Name of Amount of Date you Nature of Is Date Date of Nature of Class Acquired Acquisition **Person from** this Donor **Securities** Payment Payment *

	Transaction	Whom Acquired	a Acquirec Gift?	Acquired	
Common	Performance Stock 05/29/2020 Award/Restricted Stock Award	Charles River Laboratories		700	05/29/2020 Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph LaPlume c/o Charles River Laboratories 251 Ballardvale Street Wilmington MA 01887	Common	05/12/2023 9	959	185089
Joseph LaPlume c/o Charles River Laboratories 251 Ballardvale Street Wilmington MA 01887	Common	05/15/2023 3	345	65658

144: Remarks and Signature

Remarks 08/10/2023 Date of Notice **ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Joseph LaPlume

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)